Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System

Sensorineural Hearing Loss Clinical Trial

Official title:

Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00678899
• Other study ID #: CORP5180
• Status: Completed
• Phase: N/A
• First received: May 14, 2008
• Last updated: June 19, 2015
• Start date: April 2008
• Est. completion date: July 2014

Study information

• Verified date: June 2015
• Source: Cochlear
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy associated with the provision of acoustic and electric sound processing to individuals who demonstrate significant residual low-frequency hearing and profound high-frequency (above 1500 Hz) sensorineural hearing loss. Delivery of acoustic-electric stimulation will be provided by the Nucleus Hybrid L24 cochlear implant system.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: July 2014
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Eighteen years of age or older at the time of implantation.

2. Severe to profound (a threshold average of 2000, 3000, & 4000 Hz > 75dB HL) sensorineural hearing loss for frequencies > 1500 Hz. Low-frequency thresholds up to and including 500 Hz should be no poorer than 60 dB HL.

3. Consonant Nucleus Consonant (CNC) monosyllabic word recognition score (mean of two lists) between 10% and 60%, inclusive (i.e., 10% <= score <= 60%), in the ear to be implanted.

4. CNC word recognition score in the contralateral ear equal to, or better than, the ear to be implanted but not more than 80%.

5. English spoken as a primary language.

Exclusion Criteria:

1. Duration of severe-to-profound hearing loss greater than 30 years.

2. Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age).

3. Medical or psychological conditions that contraindicate undergoing surgery.

4. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array.

5. Conductive overlay of 15 dB or greater at two or more frequencies, in the range 250 to 1000 Hz.

6. Hearing loss of neural or central origin.

7. Diagnosis of Auditory Neuropathy.

8. Active middle-ear infection.

9. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices.

10. Unwillingness or inability of the candidate to comply with all investigational requirements.

11. Additional handicaps that would prevent or restrict participation in the audiological evaluations.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hearing Loss
• Hearing Loss, Sensorineural
• Sensorineural Hearing Loss

Intervention

Device:
• Nucleus Hybrid L24
Implantation with Nucleus Hybrid L24 cochlear implant

Locations

Country	Name	City	State
United States	NYU Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Cochlear

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Consonant Nucleus Consonant (CNC) Monosyllabic Word Score-Treated Ear (CO-PRIMARY)	The co-primary study endpoints will be statistically significant differences between the mean, preoperative monosyllabic CNC word score (unilateral acoustic, ear to be implanted) and the postoperative monosyllabic CNC word scores (Hybrid mode) for the activated, Hybrid L24 cochlear implant subjects.; The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field and scored as a total number of words correct, which will be expressed as a percentage correct for this study.	6 Months Postactivation	No
Primary	AzBio Sentence Score in Noise - Treated Ear (Co-Primary)	The co-primary study endpoints will be statistically significant differences between the mean, preoperative AzBio Sentences score in noise (unilateral acoustic, ear to be implanted) and postoperative AzBio Sentences score in noise (Hybrid mode) for the activated, Hybrid L24 cochlear implant subjects.; The AzBio Sentence Test consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in' unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts towards the overall score.	6 Months Postactivation	No
Secondary	Consonant Nucleus Consonant (CNC) Monosyllabic Words - Treated Ear	Secondary efficacy endpoints using binomial comparisons (based on the postoperative Hybrid condition) are as follows: The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field. The percentage of subjects that scored equal to or better than they did in the pre-operative unilateral acoustic-only condition will be reported.	6 Months Postactivation	No
Secondary	AzBio Sentence Score-Treated Ear	Secondary efficacy endpoints using binomial comparisons (based on the postoperative Hybrid condition) are as follows: The AzBio Sentence Test consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in'unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts toward the overall score. The percentage of subjects that scored equal to or better than they did in the pre-operative acoustic only condition will be reported.	6 Months Postactivation	No